arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Syndax Pharmaceuticals Inc

SNDX

$20.41 ▲ +0.64 (+3.24%) at close

13 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Syndax Pharmaceuticals Inc faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.8B

Dividend Yield —

Revenue Growth 627.8%

Op. Margin -158.4%

ROIC -333.8% ↘

FCF / Share $-3.73 ↘

Trailing P/E —

Price / Book 27.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

13-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$172.35M

↑ +627.8% —

Net Income Profit after all expenses

$-285.42M

↑ +10.5% —

Operating Margin Operating profit as % of sales

-158.4%

↓ -944.3% 1th

FCF / Share Free cash flow per share

$-3.73

↓ -16.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Revenue Growth YoY (%)	627.8% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+7748%)	—	—	N/M	9109.6% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+113769%)	0.0% Caution ↓ Caution Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-100%)	0.0% Caution ↓ Caution Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-100%)	-28.0% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-450%)	72.8% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+810%)	94.6% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1082%)	—	—	—
EPS Growth YoY (%)	11.6% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-24.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-21.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	10.5% Fair ↑ Fair Improving Year-over-year change in net income	-52.3% Weak Weak Year-over-year change in net income	-40.2% Weak Weak Year-over-year change in net income	N/M	N/M	-30.5% Weak ↓ Weak Declining Year-over-year change in net income	24.2% Good ↑ Good Improving Year-over-year change in net income	-21.6% Weak ↑ Weak Improving Year-over-year change in net income	-36.7% Weak ↑ Weak Improving Year-over-year change in net income	-84.4% Weak Weak Year-over-year change in net income	-21.6% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-16.2% Weak ↑ Weak Improving Year-over-year change in free cash flow	-40.7% Weak Weak Year-over-year change in free cash flow	-3.7% Weak Weak Year-over-year change in free cash flow	N/M	N/M	—	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	—	-44.7% Weak Weak Compound annual revenue growth over 3 years	—	—	351.6% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	-10.4% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	7.5% Fair Fair Compound annual revenue growth over 3 years	34.2% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—	—
Revenue CAGR 5Y (%)	157.7% Excellent Excellent Compound annual revenue growth over 5 years	73.3% Excellent Excellent Compound annual revenue growth over 5 years	—	—	158.1% Excellent Excellent Compound annual revenue growth over 5 years	19.3% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Operating Margin (%) (%)	-158.4% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1156%)	—	—	—	18.8% Good Good Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+25%)	—	—	—	—	—	—	—	—
Profit Margin (%) (%)	-165.6% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1480%)	—	—	—	17.8% Good Good Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+49%)	—	—	—	—	—	—	—	—
FCF Margin (%) (%)	-187.5% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	20.8% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—	—	—	—
FCF / Net Income (x)	1.13x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.16x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.78x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Return on Invested Capital (%)	-333.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-93.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-32.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-25.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	5.1% Caution ↑ Caution Improving Return earned on debt + equity capital invested Optimal: > 10%	-22.4% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-143.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-113.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-46.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-41.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	6.4% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	11.0% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-51.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-46.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-37.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-30.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	5.8% Caution ↑ Caution Improving Operating profit relative to total assets Optimal: > 10%	-23.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-90.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-90.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-45.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-40.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-22.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	—	-110.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-838%)	-37.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-352%)	-31.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-313%)	6.1% Caution ↑ Caution Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-59%)	-29.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-293%)	-177.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1282%)	-139.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1030%)	-58.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-489%)	-52.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-452%)	9.6% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-36%)	13.0% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-13%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Interest Coverage (x)	—	—	-1105.55x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-48.38x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	13.81x Excellent Excellent Operating income divided by interest expense Optimal: > 5x	-30.30x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—	—
Net Debt (USD)	$-134.93M	$-154.08M	$-295.39M	$-74.36M	$-221.97M	$-115.24M	$-24.61M	$-33.77M	$-35.17M	$-23.84M	$-23.18M	$-10.01M	$-10.10M

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Revenue per Share (USD)	$1.99	$0.28	$0.00	$0.00	$2.68	$0.04	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-3.29	$-3.72	$-2.98	$-2.46	$0.48	$-1.87	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-3.73	$-3.21	$-2.28	$-2.20	$0.56	$-1.73	—	—	—	—	—	—	—
Book Value per Share (USD)	$0.74	$3.36	$6.53	$6.86	$7.43	$5.27	$1.16	$2.14	$4.28	$4.62	—	—	—
Tangible Book Value per Share (USD)	$0.74	$3.36	$6.53	$6.86	$7.43	$5.27	$1.16	$2.14	$4.28	$4.62	—	—	—
Basic Weighted Avg Shares (shares)	86.63M	85.62M	70.37M	60.76M	52.06M	41.31M	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Working Capital (USD)	$407.96M	$499.51M	$522.78M	$460.72M	$427.71M	$279.99M	$43.96M	$67.24M	$117.64M	$98.14M	$83.16M	—	—
Total Equity (USD)	$64.63M	$288.12M	$554.20M	$467.45M	$408.37M	$252.19M	$31.60M	$53.05M	$104.32M	$84.14M	$-252.41M	$-152.57M	$-128.47M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Sales/Revenue/Turnover (USD)	$172.35M	$23.68M	$0.00	$0.00	$139.71M	$1.52M	$1.52M	$1.52M	$2.11M	$1.22M	$627.00K	—	—
Depreciation Expense (USD)	$6.00M	$8.00M	$12.00M	$33.00M	$43.00M	$90.00K	$92.00K	$78.00K	$76.00K	$89.00K	$21.00K	$15.00K	—
Net Income, GAAP (USD)	$-285.42M	$-318.76M	$-209.36M	$-149.34M	$24.93M	$-73.16M	$-56.05M	$-73.96M	$-60.80M	$-44.47M	$-24.12M	$-19.83M	—
Operating Cash Flow (USD)	$-322.98M	$-274.90M	$-160.60M	$-133.68M	$29.13M	$-71.26M	$-50.61M	$-68.53M	$-47.37M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 13 years · 47 quarters

Syndax Pharmaceuticals Inc

Analytical Summary

13-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare SNDX with peers